CorMedix Inc. (CRMD)
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
CorMedix Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 77.94M shares outstanding
USCorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally.
Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007.
Its corporate headquarters are located in Berkeley Heights, New Jersey.
Leadership
Alan W. Dunton
Director
Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Elizabeth Hurlburt
Executive VP and Chief Operating & Commercial Officer
Gregory Duncan
Director
Employees
191
Country
US
Sector
Healthcare
Website
cormedix.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Dillione Janet | Director | Option Exercise | 48.9K | -- | Sep 18, 2026 |
| Dillione Janet | Director | Option Exercise | 48.9K | -- | Sep 18, 2026 |
 Hurlburt Elizabeth | Chief Operating Officer | Automatic Sell | 8.1K | $67.0K | Aug 29, 2026 |
 Blum Susan | Chief Financial Officer | Automatic Sell | 8.4K | $69.9K | Aug 29, 2026 |
 Zelnick Kaufman Beth | Chief Legal Officer | Automatic Sell | 8.4K | $69.9K | Aug 29, 2026 |
| Hurlburt Elizabeth | Chief Operating Officer | Grant/Award | 36.0K | -- | Feb 4, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 6.3M | 8.1% | 13F |
Deep Track Capital, LP | 6.3M | 8.0% | 13F |
Deep Track Capital, LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 6.3M | 8.0% | 13G |
SHAIBATALHAMD AYMEN ABDALKADER · may incl. warrants· filed Jun 2026 | 4.6M | 5.9% | 13G |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Feb 2025 | 4.6M | 5.9% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | 4.0% | 13F |
STATE STREET CORP | 2.3M | 3.0% | 13F |
ROYCE & ASSOCIATES LP | 2.2M | 2.8% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 1.9M | 2.5% | 13F |
UBS Group AG | 1.9M | 2.4% | 13F |
Insiders
- Dillione JanetDirector
- Hurlburt ElizabethChief Operating Officer
- Blum SusanChief Financial Officer
- Zelnick Kaufman BethChief Legal Officer
- Todisco JosephChief Executive Officer
- DUNTON ALAN WDirector
- Stewart Robert ADirector
- Duncan Gregory ScottDirector
- Kaplan MyronDirector
- Lefkowitz Steven WDirector
based on 77.94M shares outstanding
US30d Avg
1.08M
60d Avg
971.01K
90d Avg
1.13M